My final idea that could be ready to trigger a major breakout trade is biotechnology and drugs player Sarepta Therapeutics (SRPT), which is focused on the discovery and development of RNA-based therapeutics for the treatment of both rare and infectious diseases.
If you look at the chart for Sarepta Therapeutics, you'll notice that this stock has experienced two sharp spikes higher this week off of some near-term support at $9 a share with strong upside volume. Volume for those spikes was 3.9 million and 1.6 million shares, which is well above its three-month average volume of 821,273 shares. Following those spikes, shares of SRPT have so far been holding its gains, which is bullish technical action. This price trend is quickly pushing SRPT within range of triggering a major near-term breakout trade.
Traders should now look for long-biased traders in SRPT once it manages to clear some near-term overhead resistance at $10.78 a share with high volume. Look for a sustained move or close above $10.78 with volume that hits near or above its three-month average action of 821,273 shares. If that breakout triggers soon, then SRPT will have a great chance of hitting $12 to $13 a share in the near-term, or possibly even higher.One could look to get long SRPT off weakness, and simply use a stop right around that key near-term support level at $9 a share. A better bet might be to get long once SRPT sustains a move or close above $10.78 with high volume, and simply use a stop right below $10 a share. Either way, I would avoid long trades below $9, and stalk this for a breakout over $10.78 a share. To see more breakout candidates, check out the Breakout Stocks of the Week portfolio on Stockpickr. -- Written by Roberto Pedone in Winderemere, Fla.
Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV